Psilera, a biopharmaceutical company focused on next-generation psychedelics and neuroplastogens, announced on Tuesday a new method for synthesising novel libraries of next-generation neuroplastogens in the ACS Omega Journal.

By gaining never-before-seen functionality with the base scaffold of psychedelics like psilocybin, N,N-DMT, and 5-MeO-DMT, Psilera says that it can explore new chemical space to produce next-generation neuroplastogens with targeted therapeutic effects.

The publication, Synthesis and Biological Evaluation of 4-bromo-N,N-dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development, led by Psilera's director of Medicinal Chemistry, Elena Bray, PhD, illustrates successful intermolecular carbon-to-carbon bonding on the 4-position of tryptamines. The data gathered in coordination with the Designer Drug Research Unit at the National Institute on Drug Abuse (NIDA) demonstrates 4-Br-DMT as a synthetic building block capable of expanding and diversifying Psilera's robust small-molecule neuroplastogen library.

While not a drug itself, 4-Br-DMT is a late-stage intermediate that can yield important new neuroplastogens within Psilera's patent-protected strategy. According to Psilera, this new synthetic tool provides a unique opportunity to engineer novel tryptamine derivatives as neuroplastogens, and highlights the breadth of its pipeline beyond PSIL-006.